Cargando…

Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies and is known for its high resistance and low response to treatment. Tumor immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Karyopherin alpha 2 (KPNA2), a member of the nucl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Kai-Xia, Huang, Shan, Hu, Li-Peng, Zhang, Xue-Li, Qin, Wei-Ting, Zhang, Yan-Li, Yao, Lin-Li, Yu, Yanqiu, Zhou, Yao-Qi, Zhu, Lei, Ji, Jianguang, Zhang, Zhi-Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939744/ https://www.ncbi.nlm.nih.gov/pubmed/33728352 http://dx.doi.org/10.1155/2021/6694392

Ejemplares similares

Nuclear import of prototype foamy virus transactivator Bel1 is mediated by KPNA1, KPNA6 and KPNA7
por: Duan, Jihui, et al.
Publicado: (2017)

Nuclear import of prototype foamy virus transactivator Bel1 is mediated by KPNA1, KPNA6 and KPNA7
por: Duan, Jihui, et al.
Publicado: (2016)

Aberrant expression of KPNA2 is associated with a poor prognosis and contributes to OCT4 nuclear transportation in bladder cancer
por: Zhou, Jingcheng, et al.
Publicado: (2016)

Immune-related somatic mutation genes are enriched in PDACs with diabetes
por: Wang, Kaixuan, et al.
Publicado: (2019)

An epilepsy-associated mutation in the nuclear import receptor KPNA7 reduces nuclear localization signal binding
por: Oostdyk, Luke T., et al.
Publicado: (2020)

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
por: Wang, Xiuchao, et al.
Publicado: (2020)

Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics
por: Hu, Li-Peng, et al.
Publicado: (2021)

USP22 promotes IRF3 nuclear translocation and antiviral responses by deubiquitinating the importin protein KPNA2
por: Cai, Zeng, et al.
Publicado: (2020)

Value of KPNA4 as a diagnostic and prognostic biomarker for hepatocellular carcinoma
por: Xu, Mingxing, et al.
Publicado: (2021)

Knockdown of KPNA2 inhibits autophagy in oral squamous cell carcinoma cell lines by blocking p53 nuclear translocation
por: Lin, Feng, et al.
Publicado: (2018)

Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion
por: Xia, Xichun, et al.
Publicado: (2018)

PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?
por: Narayanan, Shruthi, et al.
Publicado: (2021)

LncRNA DLEU1 contributes to colorectal cancer progression via activation of KPNA3
por: Liu, Tianyou, et al.
Publicado: (2018)

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer
por: Alshareeda, A T, et al.
Publicado: (2015)

KPNA2 promotes metabolic reprogramming in glioblastomas by regulation of c-myc
por: Li, Jie, et al.
Publicado: (2018)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Cytosolic and nuclear recognition of virus and viral evasion
por: Li, Siji, et al.
Publicado: (2021)

Multiomics-based analyses of KPNA2 highlight its multiple potentials in hepatocellular carcinoma
por: Zhang, Jinzhong, et al.
Publicado: (2021)

SMAD4 Y353C promotes the progression of PDAC
por: Wang, Zusen, et al.
Publicado: (2019)

KPNA2 promotes renal cell carcinoma proliferation and metastasis via NPM
por: Zheng, Song, et al.
Publicado: (2021)

SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells
por: Li, Siqin, et al.
Publicado: (2016)

Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression
por: Li, Xiao-Lei, et al.
Publicado: (2013)

KPNA2 promotes angiogenesis by regulating STAT3 phosphorylation
por: Jia, Yujie, et al.
Publicado: (2022)

Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
por: Zhou, Xu, et al.
Publicado: (2023)

MUC4-promoted neural invasion is mediated by the axon guidance factor netrin-1 in PDAC
por: Wang, Linjun, et al.
Publicado: (2015)

Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
por: Dai, Manxiong, et al.
Publicado: (2022)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020)

SMARCC1 Enters the Nucleus via KPNA2 and Plays an Oncogenic Role in Bladder Cancer
por: Wei, Zhengmao, et al.
Publicado: (2022)

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition
por: Hu, Bo, et al.
Publicado: (2019)

Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
por: Liao, Wei‐Chao, et al.
Publicado: (2021)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
por: Zhang, Yangyang, et al.
Publicado: (2023)

LINC00467 facilitates osteosarcoma progression by sponging miR-217 to regulate KPNA4 expression
por: Yan, Jing, et al.
Publicado: (2021)

Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2022)

KPNA2 interaction with CBX8 contributes to the development and progression of bladder cancer by mediating the PRDM1/c-FOS pathway
por: Zeng, Fanchang, et al.
Publicado: (2021)

The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation
por: Liu, Chao, et al.
Publicado: (2023)

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
por: Yu, Zheng-Zheng, et al.
Publicado: (2023)

LncRNA SNHG6 Upregulates KPNA5 to Overcome Gemcitabine Resistance in Pancreatic Cancer via Sponging miR-944
por: Gao, Ge, et al.
Publicado: (2023)

Prognostic value of increased KPNA2 expression in some solid tumors: A systematic review and meta-analysis
por: Zhou, Li-Na, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h2gacjpqr3f8q3nf6qcvot0rqc